Switzerland · Delayed Price · Currency is CHF BioVersys AG Statistics
Total Valuation
BioVersys AG has a market cap or net worth of CHF 159.53 million. The enterprise value is 112.40 million.
| Market Cap | 159.53M |
| Enterprise Value | 112.40M |
Important Dates
The last earnings date was Wednesday, September 9, 2026.
| Earnings Date | Sep 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioVersys AG has 5.87 million shares outstanding. The number of shares has increased by 31.25% in one year.
| Current Share Class | 5.87M |
| Shares Outstanding | 5.87M |
| Shares Change (YoY) | +31.25% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 10.26% |
| Owned by Institutions (%) | 10.23% |
| Float | 3.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.51 |
| PB Ratio | 3.56 |
| P/TBV Ratio | 3.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 24.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.86, with a Debt / Equity ratio of 0.49.
| Current Ratio | 7.86 |
| Quick Ratio | 7.17 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.86 |
| Interest Coverage | -20.71 |
Financial Efficiency
Return on equity (ROE) is -46.05% and return on invested capital (ROIC) is -20.27%.
| Return on Equity (ROE) | -46.05% |
| Return on Assets (ROA) | -18.32% |
| Return on Invested Capital (ROIC) | -20.27% |
| Return on Capital Employed (ROCE) | -37.42% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 121,658 |
| Profits Per Employee | -695,000 |
| Employee Count | 38 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BioVersys AG has paid 30,000 in taxes.
| Income Tax | 30,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.19% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -17.19% |
| 50-Day Moving Average | 26.79 |
| 200-Day Moving Average | 25.90 |
| Relative Strength Index (RSI) | 52.67 |
| Average Volume (20 Days) | 2,473 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioVersys AG had revenue of CHF 4.62 million and -26.41 million in losses. Loss per share was -4.51.
| Revenue | 4.62M |
| Gross Profit | 4.62M |
| Operating Income | -25.16M |
| Pretax Income | -26.38M |
| Net Income | -26.41M |
| EBITDA | -25.04M |
| EBIT | -25.16M |
| Loss Per Share | -4.51 |
Balance Sheet
The company has 69.31 million in cash and 22.18 million in debt, with a net cash position of 47.14 million or 8.04 per share.
| Cash & Cash Equivalents | 69.31M |
| Total Debt | 22.18M |
| Net Cash | 47.14M |
| Net Cash Per Share | 8.04 |
| Equity (Book Value) | 44.84M |
| Book Value Per Share | 7.66 |
| Working Capital | 66.30M |
Cash Flow
In the last 12 months, operating cash flow was -25.35 million and capital expenditures -312,000, giving a free cash flow of -25.66 million.
| Operating Cash Flow | -25.35M |
| Capital Expenditures | -312,000 |
| Depreciation & Amortization | 120,000 |
| Net Borrowing | 2.65M |
| Free Cash Flow | -25.66M |
| FCF Per Share | -4.38 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -544.24% |
| Pretax Margin | -570.63% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioVersys AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.25% |
| Shareholder Yield | -31.25% |
| Earnings Yield | -16.55% |
| FCF Yield | -16.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for BioVersys AG is 65.05, which is 139.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 65.05 |
| Price Target Difference | 139.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 102.33% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioVersys AG has an Altman Z-Score of 0.85 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.85 |
| Piotroski F-Score | 1 |